Page 460 - Williams Hematology ( PDFDrive )

434 Part V: Therapeutic Principles Chapter 28: Therapeutic Apheresis: Indications, Efficacy, and Complications 435

65. Tan KR, Wiegand RE, Arguin PM: Exchange transfusion for severe malaria: Evidence 96. Porcu P, Cripe LD, Ng EW, et al: Hyperleukocytic leukemias and leukostasis: A review
base and literature review. Clin Infect Dis 57:923, 2013. of pathophysiology, clinical presentation and management. Leuk Lymphoma 39:1, 2000.
66. Amaratunga C, Sreng S, Suon S, et al: Artemisinin-resistant Plasmodium falciparum in 97. Slats AM, Egeler RM, van der Does-van den Berg A, et al: Causes of death–other than
Pursat province, western Cambodia: A parasite clearance rate study. Lancet Infect Dis progressive leukemia–in childhood acute lymphoblastic (ALL) and myeloid leukemia
12:851, 2012. (AML): The Dutch Childhood Oncology Group experience. Leukemia 19:537, 2005.
67. World Health Organization: Global Plan for Artemisinin Resistance Containment 98. Bruserud Ø, Liseth K, Stamnesfet S, et al: Hyperleukocytosis and leukocytapheresis in
(GPARC). HO Press, Geneva, 2011. Available online at http://www.who.int/malaria/ acute leukemias: Experience from a single centre and review of the literature of leuko-
publications/atoz/artemisinin_resistance_containment_2011.pdf (accessed 6 June cytapheresis in acute myeloid leukaemia. Transfus Med 23:397, 2013.
2014). 99. Oberoi S, Lehrnbecher T, Phillips B, et al: Leukapheresis and low-dose chemotherapy
68. Ariey F, Witkowski B, Amaratunga C, et al: A molecular marker of artemisinin-resistant do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: A system-
Plasmodium falciparum malaria. Nature 505:50, 2014. atic review and meta-analysis. Leuk Res 38:460, 2014.
69. Vannier E, Krause PJ: Human babesiosis. N Engl J Med 366:2397, 2012. 100. Pastore F, Pastore A, Wittmann G, et al: The role of therapeutic leukapheresis in hyper-
70. Rosner F, Zarrabi MH, Benach JL, et al: Babesiosis in splenectomized adults. Review of leukocytotic AML: PLoS One 9(4): E95062, 2014.
22 reported cases. Am J Med 76:696, 1984. 101. Lowe EJ, Pui C-H, Hancock ML, et al: Early complications in children with acute lym-
71. Evenson DA, Perry E, Kloster B, et al: Therapeutic apheresis for babesiosis. J Clin Apher phoblastic leukemia presenting with hyperleukocytosis. Pediatr Blood Cancer 45:10,
13:32, 1998. 2005.
72. U.S. Food and Drug Administration: Fatalities Reported to FDA Following Blood Collec- 102. Schaefer AI: Thrombocytosis. N Engl J Med 350:1211, 2004.
tion and Transfusion: Annual Summary for Fiscal Year 2013. Available online at http:// 103. Griesshammer M, Bangertner M, Sauer T: Aetiology and clinical significance of throm-
www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/Transfu- bocytosis: Analysis of 732 patients with an elevated platelet count. J Intern Med 245:295,
sionDonationFatalities/ucm391574.htm (accessed 9 June 2014). 1999.
73. Centers for Disease Control and Prevention (CDC): Babesiosis surveillance—18 states, 104. Greist A: The role of blood component removal in essential and reactive thrombocyto-
2011. MMWR Morb Mortal Wkly Rep 61:505, 2012. sis. Ther Apher 6:36, 2002.
74. Spaete J, Patrozou E, Rich JD, Sweeney JD: Red cell exchange transfusion for babesiosis 105. Denton A, Davis P: Extreme thrombocytosis in admissions to paediatric intensive care:
in Rhode Island. J Clin Apher 24:97, 2009. No requirement for treatment. Arch Dis Child 92:515, 2007.
75. Werch J, Todd C: Resolution by erythrocytapheresis of the exposure of an Rh-negative 106. Schafer AI: Bleeding and thrombosis in myeloproliferative disorders. Blood 64:1, 1984.
person to Rh-positive cells: An alternative treatment. Transfusion 33:530, 1993. 107. Baron BW, Mick R, Baron JM: Combined plateletpheresis and cytotoxic chemotherapy
76. Hale GA, Reece DE, Munn RK, et al: Blood tacrolimus concentrations in bone marrow for symptomatic thrombocytosis in myeloproliferative disorders. Cancer 72:1209, 1993.
transplant patients undergoing plasmapheresis. Bone Marrow Transplant 25:449, 2000. 108. Taft EG, Babcock RB, Scharfman WB, et al: Plateletpheresis in the management of
77. McCarthy H, Inward C, Marriage S, et al: Red cell exchange transfusion as a rescue thrombocytosis. Blood 50:927, 1977.
therapy for tacrolimus toxicity in a paediatric renal transplant. Pediatr Nephrol 26:2245, 109. Panlilio AL, Reiss RF: Therapeutic plateletpheresis in thrombocythemia. Transfusion
2011. 19:147, 1979.
78. Golden PJ, Weinstein R: Treatment of high-risk, refractory acquired methemoglob- 110. Goldfinger D, Thompson R, Lowe C: Long-term plateletpheresis in the management of
inemia with automated red blood cell exchange. J Clin Apher 13:28, 1998. primary thrombocytosis. Transfusion 19:336, 1979.
79. Streiff, MB, Smith B, Spivak JL: The diagnosis and management of polycythemia vera 111. Orlin JB, Berkman EM: Improvement of platelet function following plateletpheresis in
in the era since the Polycythemia Vera Study Group: A survey of American Society of patients with myeloproliferative diseases. Transfusion 20:540, 1980.
Hematology members’ practice patterns. Blood 99:1144, 2002. 112. Janetzko K, Weber K, Klüter H, et al: Efficiency of the cell separator AMICUS for plate-
80. Tefferi A: Polycythemia vera: A comprehensive review and clinical recommendations. let depletion in the treatment of essential thrombocythemia. J Clin Apher 16:33, 2001.
Mayo Clin Proc 78:174, 2003. 113. Yamaguchi K, Hisano M, Sakata M, et al: Periodic plateletpheresis during pregnancy in
81. Barton JC, McDonnell SM, Adams PC, et al: Diagnosis and management of hemochro- a high-risk patient with essential thrombocythemia. J Clin Apher 21:256, 2006.
matosis. Ann Intern Med 129:932, 1998. 114. Raval JS, Redner RL, Kiss JE: Plateletpheresis for postsplenectomy rebound thrombo-
82. Brissot P, de Bels, F: Current approaches to the management of hemochromatosis. cytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.
Hematology 36, 2006. J Clin Apher 28:321, 2013.
83. Valbonesi M, Bruni R: Clinical application of therapeutic erythrocytapheresis (TEA). 115. Natelson EA: Extreme thrombocytosis and cardiovascular surgery. Risks and manage-
Transfus Sci 22:183, 2000. ment. Tex Heart Inst J 39:792, 2012.
84. Oechslin E: Hematological management of the cyanotic adult with congenital heart 116. Ward DM: Extracorporeal photopheresis: How, when and why? J Clin Apher 26:276,
disease. Int J Cardiol 97:109, 2004. 2011.
85. Kaboth U, Rumpf KW, Lipp T, et al: Treatment of polycythemia vera by isovolemic 117. Centers for Medicare and Medicaid Services: Decision Memo for Extracorporeal Pho-
large-volume erythrocytapheresis. Klin Wochenschr 68:18, 1990. topheresis (CAG-00324R). (December 19, 2006.), Available online at http://www.
86. Liersch T, Vehmeyer K, Kaboth U: Large volume, isovolemic erythrocytapheresis in cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=255
treatment of polycythemia vera. Effect of massive iron depletion of proliferation behav- (accessed 2 January 2015).
ior of erythroid precursor cells (BFU-E). Med Klin (Munich) 90:390, 1995. 118. Babic AM: Extracorporeal photopheresis: Lighting the way to immunomodulation. Am
87. Zoller WG, Kellner H, Spengel FA: Erythrocytapheresis. A method for rapid extra- J Hematol 83:589, 2008.
corporeal elimination of erythrocytes. Results in 65 patients. Klin Wochenschr 66:404, 119. Yoo EK, Rook AH, Elenitsas R, et al: Apoptosis induction by ultraviolet light A and
1988. photochemotherapy in cutaneous T-cell lymphoma: Relevance to mechanism of thera-
88. Conte D, Mandelli C, Cesana M, et al: Effectiveness of erythrocytapheresis in idiopathic peutic action. J Invest Dermatol 107:235, 1996.
hemochromatosis. Report of 14 cases. Int J Artif Organs 12:59, 1989. 120. Tambur AR, Ortegel JW, Morales A, et al: Extracorporeal photopheresis induces lym-
89. Kellner H, Zoller WG: Repeated isovolemic large-volume erythrocytapheresis in the phocyte but not monocyte apoptosis. Transplant Proc 32:747, 2000.
treatment of idiopathic hemochromatosis. Z Gastroenterol 30:779, 1992. 121. Fimiani M, Di Renzo M, Rubegni P: Mechanism of action of extracorporeal photoche-
90. Cesana M, Mandelli C, Tiribelli C: Concomitant primary hemochromatosis and motherapy in chronic graft-versus-host disease. Br J Dermatol 150:1055, 2004.
beta-thalassemia trait: Iron depletion by erythrocytapheresis and desferrioxamine. Am 122. Gorgun G, Miller KB, Foss FM: Immunologic mechanisms of extracorporeal photoche-
J Gastroenterol 84:150, 1989. motherapy in chronic graft-versus-host disease. Blood 100:941, 2002.
91. Fernández-Mosterín N, Salvador-Osuna C, García-Erce JA, et al: Comparison between 123. Lamioni A, Parisi F, Isacchi G, et al: The immunological effects of extracorporeal pho-
phlebotomy and erythrocytapheresis of iron overload in patients with HFE gene muta- topheresis unraveled: Induction of tolerogenic dendritic cells in vitro and regulatory
tions. Med Clin (Barc) 127:409, 2006. T cells in vivo. Transplantation 79:846, 2005.
92. Rombout-Sestrienkova E, Nieman FHM, Essers BAB, et al: Erythrocytapheresis versus 124. McKenna KE, Whittaker S, Rhodes LE, et al: Evidence-based practice of photopheresis
phlebotomy in the initial treatment of HFE hemochromatosis patients: Results from a 1987-2001: A report of a workshop of the British Photodermatology Group and the UK
randomized trial. Transfusion 52:470, 2012. Skin Lymphoma Group. Br J Dermatol 154:7, 2006.
93. Bunin NJ, Pui C-H: Differing complications of hyperleukocytosis in children with acute 125. Zic JA: The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol
lymphoblastic or acute nonlymphoblastic leukemia. J Clin Oncol 3:1590, 1985. Ther 16:337, 2003.
94. Dutcher JP, Schiffer CA, Wiernik PH: Hyperleukocytosis in adult acute nonlympho- 126. Marques MB, Tuncer HH: Photopheresis in solid organ transplant rejection. J Clin
cytic leukemia: Impact on remission rate and duration, and survival. J Clin Oncol Apher 21:72, 2006.
5:1364, 1987. 127. Choi J, Foss FM: Photopheresis, in Apheresis: Principles and Practice, 3rd ed, edited
95. Ventura GJ, Hester JP, Smith TL, et al: Acute myeloblastic leukemia with hyperleukocy- by BC McLeod, R Weinstein, JL Winters, AM Szczepiorkowski, p 615. AABB Press,
tosis: Risk factors for early mortality in induction. Am J Hematol 27:34, 1988. Bethesda, MD, 2010.

Kaushansky_chapter 28_p0427-0436.indd 435 9/17/15 6:05 PM